These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30616523)

  • 41. Brain Metastasis Organotropism.
    Yuzhalin AE; Yu D
    Cold Spring Harb Perspect Med; 2020 May; 10(5):. PubMed ID: 31548224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer.
    Yao P; Liang S; Liu Z; Xu C
    Front Immunol; 2024; 15():1343316. PubMed ID: 38361933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles.
    Steindl A; Brastianos PK; Preusser M; Berghoff AS
    Neurooncol Adv; 2021 Nov; 3(Suppl 5):v35-v42. PubMed ID: 34859231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vascular characterization reveals immunomodulatory targets for brain metastases.
    Lugano R; Dimberg A
    Cancer Cell; 2024 Mar; 42(3):328-330. PubMed ID: 38366590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
    Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T
    Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
    Conroy JM; Pabla S; Nesline MK; Glenn ST; Papanicolau-Sengos A; Burgher B; Andreas J; Giamo V; Wang Y; Lenzo FL; Bshara W; Khalil M; Dy GK; Madden KG; Shirai K; Dragnev K; Tafe LJ; Zhu J; Labriola M; Marin D; McCall SJ; Clarke J; George DJ; Zhang T; Zibelman M; Ghatalia P; Araujo-Fernandez I; de la Cruz-Merino L; Singavi A; George B; MacKinnon AC; Thompson J; Singh R; Jacob R; Kasuganti D; Shah N; Day R; Galluzzi L; Gardner M; Morrison C
    J Immunother Cancer; 2019 Jan; 7(1):18. PubMed ID: 30678715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.
    Ma K; Lu Y; Jiang S; Tang J; Li X; Zhang Y
    Front Pharmacol; 2018; 9():1430. PubMed ID: 30618738
    [No Abstract]   [Full Text] [Related]  

  • 49. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
    Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
    Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
    Pujol JL; Greillier L; Audigier-Valette C; Moro-Sibilot D; Uwer L; Hureaux J; Guisier F; Carmier D; Madelaine J; Otto J; Gounant V; Merle P; Mourlanette P; Molinier O; Renault A; Rabeau A; Antoine M; Denis MG; Bommart S; Langlais A; Morin F; Souquet PJ
    J Thorac Oncol; 2019 May; 14(5):903-913. PubMed ID: 30664989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
    Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
    Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Xu Z; Yi F; Yu D; Xu J; Wei Y; Zhang W
    Cancer Med; 2019 Feb; 8(2):629-642. PubMed ID: 30628185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
    Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
    Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The First-week Proliferative Response of Peripheral Blood PD-1
    Kim KH; Cho J; Ku BM; Koh J; Sun JM; Lee SH; Ahn JS; Cheon J; Min YJ; Park SH; Park K; Ahn MJ; Shin EC
    Clin Cancer Res; 2019 Apr; 25(7):2144-2154. PubMed ID: 30647082
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.
    Martinez P; Peters S; Stammers T; Soria JC
    Clin Cancer Res; 2019 May; 25(9):2691-2698. PubMed ID: 30642913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
    Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
    Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors.
    Youssef A; Kasso N; Torloni AS; Stanek M; Dragovich T; Gimbel M; Mahmoud F
    Case Rep Hematol; 2018; 2018():2464619. PubMed ID: 30671268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.